

Charity Registration No. 259483 (England and Wales)

Charity Registration No. SC039207 (Scotland)

THE LEUKAEMIA CARE SOCIETY
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018

THE LEUKAEMIA CARE SOCIETY

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees C. Matthews Maxwell (Chair)
A. Podesta (Vice-chair)
W Davies (Treasurer)
Mr K Griffin
Dr M Nikolousis

President Dr R Taylor

Charity number (England and Wales) 259483

Charity number (Scotland) SC039207

Principal address 1 Birch Court
Blackpole East
Worcester
WR3 8SG

Auditor Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Bankers Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ

Solicitors Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG

THE LEUKAEMIA CARE SOCIETY

CONTENTS

	Page
Trustees' report	1 - 17
Statement of Trustees' responsibilities	18
Independent auditor's report	19 - 21
Statement of financial activities	22
Balance sheet	23
Statement of cash flows	24
Notes to the financial statements	25 - 40

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2018

The Trustees present their report and financial statements for the year ended 31 March 2018.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's governing document (Trust Deed), the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016)

Objectives and activities

The Charity operated throughout the year to achieve its objectives, which are:

- To promote the care, welfare and treatment of persons affected by leukaemia and allied blood disorders.
- To relieve the needs of families of such persons, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment, where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision as a Charity is:

"Helping people live better with blood cancer".

Our Mission is:

"Improving lives through earlier diagnosis, access to effective treatments, information and support".

All of the Society's activities are focused on providing care and support to all those affected by a diagnosis of blood cancer. Access to our services is unrestricted for all UK residents affected by such a diagnosis. In consequence, the activities deliver public benefit.

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the Charity should undertake.

Leukaemia Care is a national blood cancer support charity. We are dedicated to ensuring that anyone affected by blood cancer receives the right information, advice and support.

A diagnosis of a blood cancer can have a huge impact on someone emotionally, as well as physically. We understand that feelings of shock, anger and loneliness are all common at the time of diagnosis, during treatment and recovery, and having someone to talk to, as well as the right information available can be a huge comfort.

We not only support patients, but carers and families too who can often carry a lot of the emotional strain when someone they love is diagnosed with a blood cancer.

We focus on the support that is needed now to help those affected by blood cancer cope during a diagnosis and beyond.

The activities delivered by the charity are as follows:

- Helpline providing emotional support, information and signposting – we also handle requests through web chat and email
- Nurse Advisor service – people can contact our nurse by phone or email, Mondays, Tuesdays, Wednesdays as well as Thursday and Friday evenings or arrange for a call back when she is on shift
- Support groups – we run 24 groups nationwide including in Scotland

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

- Patient and carer conferences – we run national events giving people the opportunity to meet, share experiences and hear from leading experts in blood cancers
- Leukaemia Matters – our quarterly magazine with inspirational patient stories and information focusing on different blood cancers
- Patient information and website - our “step by step” range of booklets providing accessible information on anything related to blood cancers. Additional information as well as digital editions of our booklets and Leukaemia Matters are available through our website www.leukaemiacare.org.uk
- Phone buddy support – where we match patient and carer volunteers with anyone needing one-to-one support from someone who has experienced a similar blood cancer journey
- Education for health professionals – our annual nurse education days with continuing professional development accreditation through the Royal College of Nursing and our GP e-learning tool to support GPs to diagnose blood cancers earlier
- Campaigning, policy and lobbying work – as Leukaemia Care and collectively through cancer campaigning groups such as Cancer 52 and the Blood Cancer Alliance
- Individual advocacy – providing tailored support, information and signposting on behalf of patients needing extra help to access treatment, services or information
- Fundraising – our dedicated team raise vital funds to run our patient services

Achievements and performance

Following a consultation, Leukaemia Care refreshed its vision, mission statement, strapline and branding. Alongside this we launched a new website with greatly improved navigation in March 2018.

This was the second year of our three-year strategy covering 2016 to 2019 and was reviewed subject to outcomes from year one.

We continue to invest in patient services with a focus on leukaemias, allowing Leukaemia Care to develop its authority in this area while continuing to work in partnership with our fellow blood cancer charities.

Our main aims in 2017/18 were to

- Raise awareness of our services with patients, carers and healthcare professionals
- Raise awareness of leukaemia
- Improve our training for healthcare professionals caring for blood cancer patients

We continue to focus our plan through the nine areas detailed below:

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Providing high quality information through a variety of channels so patients and carers feel confident they have all the information they need to make informed decisions;

Our 23 patient information booklets continue to be Information Standard approved – a robust quality standard for health information in England.

Four new patient booklets published this year were A-Z of leukaemia, All about leukaemia: an easy read guide, Acute Myeloid Leukaemia treatments, Relapse and Acute Myeloid Leukaemia, and stem cell transplants. We distributed a total of 24,849 patient booklets to patients and nurses – an increase of almost 7,586 on the previous year. In addition, there were 7,721 downloads of our booklets – an increase of 4,324 on 2016/17.

This year we held conferences in Liverpool, London and Portsmouth providing 146 patients and carers with an opportunity to meet others, share experiences and hear from eminent speakers on their blood cancer. The Portsmouth conference was run jointly with the Lymphoma Association.

We are committed to helping patients and carers share their experiences and will continue to use video to provide accessible information. We produced videos on managing fatigue, exercise, neutropenia and mouthcare (viewed 39,462). Our Spot Leukaemia video – part of our Blood Cancer Awareness Month campaign was viewed 81,100 times.

Our circulation for Leukaemia Matters (formerly journey magazine) dropped following a review of our database where we contacted supporters to update their consent to communications as part of the charity's compliance with the General Data Protection Regulation Act. Circulation is currently 3,541 per quarterly issue for all subscriptions.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Providing emotional support so patients and carers feel less anxious, supported and connected to others who understand;

Following a review of our helpline, we reduced opening hours from 24/7, to Monday to Friday (9 am till 10 pm) and Saturdays (9 am to 12:30 pm) as most of the calls were received within these hours. We maintained access to a clinical nurse specialist at 28 hours per week spread over daytime and evenings.

We responded to 1,228 requests for support from patients, carers and health professionals through our helpline, web chat service, email and buddy service. The top reasons for support remain medical advice, emotional support and financial assistance.

We opened eight new support groups including our first group on Facebook. Over the course of the year, we held 95 support group meetings supporting 902 people.

Our Hospital Support Worker based at Heartlands Hospital in Birmingham and Good Hope Hospital in Sutton Coldfield supported 2,306 patients and carers during haematology clinics. Support was provided during the patient consultation (with permission of the patient and consultant haematologist) and in a private dedicated room.

Providing nurses with high quality information to support their patients so patients and carers feel their nurse understands and can support their needs;

55 nurses attended our first conference on palliative care in haematology held in London and fully accredited by the Royal College of Nursing.

Leukaemia Care awarded nine nurse bursaries in partnership with the Royal College of Nursing Foundation to support nurses caring for blood cancer patients. The bursaries contribute to specialist training for nurses as follows: childhood cancer nursing, managing children's and young people's pain, advanced assessment skills for non-medical practitioners, evidence-based decision making in healthcare, Caring for Children and Young People with Life-Limiting Conditions, Introduction and continuing care in childhood cancer nursing, clinical examination, final module of MSc in Advanced Practice in Cancer Care and a dissertation on sibling donors in bone marrow transplantation.

500 nurses subscribed to our new free quarterly magazine for haematology nurses – Nursing Matters.

We continue to work towards launching our free online learning course in leukaemias for junior nurses and clinical nurse specialists in September 2018.

Supporting GPs to recognise the symptoms of blood cancers so patients are diagnosed earlier and subsequently have better outcomes;

We continue to promote our GP e-learning tool designed to help GPs spot the early signs and symptoms of blood cancers with 467 GPs completing the course in 2017/18 with a total of 1,000 trained since its launch. GPs play a crucial role in diagnosing blood cancers early, but this is not always easy due to the vagueness of symptoms and relative rarity of this group of cancers.

Alongside our e-learning tool, Leukaemia Care piloted an in-person GP training event in partnership with the Midlands faculty of the Royal College of General Practitioners.

Bromsgrove saw 38 GPs spend the afternoon learning from consultant haematologists, patients and their peers about key indicators to aid early recognition and diagnosis of blood cancers. A major part of the event also looked at the challenges of people presenting with a blood cancer to aid communication, improvements in patient experience and outcomes.

Leukaemia Care are grateful for the commitment and support of The Royal College of General Practitioners (RCGP), event facilitator Dr Bill Strange (RCGP Midlands) and sessions given by experts: Dr Salim Shafeek (Worcester Acute Hospitals NHS Trust), Dr Manos Nikolousis (Heart of England Foundation Trust), Dr Ben Kennedy (University of Leicester) and Kris Griffin (Leukaemia Care trustee and patient).

Lessons learned from this pilot event will aid Leukaemia Care and RCGP to prepare for shaping this event for other regions during 2018/19.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Raising public awareness of blood cancers and their symptoms so people are encouraged to go to their GP and raise their concerns earlier;

SpotLeukaemia

For Blood Cancer Awareness Month (BCAM) 2017, Leukaemia Care turned spotty with our 'Spot Leukaemia' campaign.

Leukaemia Care's "Living with Leukaemia" report highlighted that although most people had heard of leukaemia, the majority didn't know anything about it. Additionally, patients did not recognise the symptoms of leukaemia, so did not suspect cancer before diagnosis.

As a result, the campaign sought to raise awareness of what leukaemia is, the symptoms to spot and who can be affected by leukaemia. Aiming to equip people to spot the signs and symptoms of leukaemia and urge them to visit their GP if they have any concerns.

Our key message was: "Leukaemia is a blood cancer that can affect people of all ages. Knowing the symptoms can save lives # SpotLeukaemia"

The six key symptoms were:

1. Fatigue
2. Bruising or bleeding
3. Bone/joint pain
4. Fever or night sweats
5. Sleeping problems
6. Shortness of breath

These were based on the most common symptoms reported by leukaemia patients prior to diagnosis in our "Living with Leukaemia" report based on the experiences of 2,019 patients who completed our survey in 2016. To reflect this, we updated our symptoms cards to produce age targeted cards.

Key achievements were

- Leukaemia Care appeared in the national press as well as in 14 regional publications.
- 67,823 people visited our website during blood cancer awareness month. 13,856 people visited the dedicated campaign page.
- We reached 3,182,929 people on social media throughout our BCAM campaign. 1,583,284 people were reached by our ThunderClap on Twitter.
- 6,500 awareness ribbons were sent out during September, as well as 14,981 symptoms cards.
- Our intention is to continue to run the campaign each year during Blood Cancer Awareness Month in September.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Campaigning for equality of access to treatment across the UK so patients can access the best available treatment in a timely manner;

We ran two campaigns in 2017/18 focusing on inequalities of access to treatment.

Campaign 1: "MyCNSMatters"

Following just 38% of leukaemia patients stating they had access to a Clinical Nurse Specialist (CNS) in the Leukaemia Care 2016 patient experience survey, we wanted to identify exactly how access to a CNS improves the experience of leukaemia patients and whether there were any issues affecting access.

Our findings

- Patients without a CNS are more likely to not understand the reasons for being placed on the 'watch and wait' scheme, more likely to feel concerned and twice as likely to not receive any supportive written information.
- Nearly all patients with a CNS felt involved in decisions about their treatment to some extent, whereas 1 in 10 patients without a CNS did not feel involved at all.
- 1 in 5 of the patients without a CNS was left either without an explanation of their results or not understanding the one that was given.
- Patients with a CNS were more likely to receive both verbal and written information about support groups; receive advice about finding further information; and more likely to be directed to trusted websites.
- 66% of patients without CNS access were also not offered any additional support, despite the majority wanting it.
- Patients without CNS access are more likely to reach out to charities for support.
- Leukaemia patients in England are more likely to have access to a CNS compared to Wales and Scotland.
- The regional variations across the UK are between 30% and 50% of patients having access to a CNS.
- CNS numbers have increased between 2015 and 2017, but approximately only 25% of trusts have leukaemia specific clinical nurse specialists.
- Shortages in the nursing workforce across the NHS have an impact on the availability of clinical nurse specialists, particularly at busy periods (e.g. the winter).

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Our Recommendations

1. Ensuring that patients are introduced to their CNS from diagnosis.
2. Increasing the specialisation of Clinical Nurse Specialists.
3. A general improvement in nursing staff levels across the NHS.

Leukaemia Care provide access to CNS's on our help line five days a week. Our regional co-ordinators visit haematology departments nationwide to raise awareness of our free patient support services and nurse education. We recognise the excellent work done by CNS's and look to provide support to patients and their families alongside this acknowledging that resources within the NHS are limited.

Gathering evidence: Leukaemia Care patient survey 2017

We published the outcomes of our 2016 patient survey in our "Living with Leukaemia" report at an event in parliament during Blood Cancer Awareness Month in September. Based on the experiences of 2,019 leukaemia patients we were able to develop 10 recommendations which we have used to focus our strategy for patient services. For example, recommendations 5 and 9 relate to watch and wait and this was the focus of our campaign in March 2018.

A copy of the report can be viewed on our website <https://www.leukaemiacare.org.uk/get-involved/our-campaigns/>

Leukaemia Care commissioned Quality Health to undertake a second survey to provide further evidence on leukaemia patient experience, with a focus on the varying needs of patients with different forms of leukaemia. 2,884 leukaemia patients – an increase of 865 on the 2016 survey took part. We are very grateful to fellow blood cancer charities who promoted the survey to their membership and helped us to capture the opinions of so many people.

The survey was structured to take the patient through their experience before diagnosis, during diagnosis, treatment and care, living with a blood cancer, the support they received, care from their GP after diagnosis, life after treatment, ongoing testing and monitoring and views on potential treatments.

The full results of our second patient experience survey will be reported in September 2018 during Blood Cancer Awareness Month, however preliminary results informed our "Watch, wait and worry" campaign.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Campaign 2: "Watch, wait and worry"

It is estimated that there are around 13,000 chronic lymphocytic leukaemia (CLL) patients living on Watch and Wait in the UK, and each year two thirds of patients newly diagnosed will be placed onto the scheme.

We want to see more patients live well with Watch and Wait, rather than 'watching and worrying'. The campaign aims to raise awareness of the issues faced by Watch and Wait patients and calls for improvements in the provision of both information and support.

The idea of Watch and Wait is to monitor the progression of a patient's blood cancer over time, through regular blood tests. Treatment will only be administered once the number of leukaemia cells has risen significantly, causing a reduction in healthy cells and subsequent problems.

The reason for Watch and Wait is that CLL is a slowly progressing (chronic) leukaemia; therefore, it can take many years for the cancer to progress to the point of needing treatment. In fact, a third of patients will never require treatment.

CLL is also currently incurable with traditional therapies. While newer treatments are on the horizon that may change this, there is currently no evidence that treating a patient in the early stages of CLL is any more beneficial than waiting until the cancer has progressed.

The Leukaemia Care 2016 patient survey revealed that patients on Watch and Wait tend to face fewer effects on their physical wellbeing and are more often able to continue their normal routine with employment, house work, and travelling etc. compared to those who require treatment. This means that despite the diagnosis, there is the possibility of living well on Watch and Wait.

The emotional burden during Watch and Wait is, however, a huge constraint on the quality of life of patients. Many patients express feeling as though their CLL is a 'ticking timebomb', as they live with the uncertainty of not knowing when, or indeed if, they will require treatment.

Patient survey findings revealed that 1 in 2 patients are left feeling concerned over being placed on Watch and Wait at diagnosis. Following diagnosis, over half of patients report feeling more depressed or anxious, with 1 in 8 of these feeling constantly depressed or anxious.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Based upon the survey findings and the experience of CLL patients, we were able to identify that lack of information and support provision are significantly contributing to patients 'watching and worrying'; a term used by many to describe the emotional impact of being diagnosed with CLL and placed on Watch and Wait.

Therefore, with the help of CLL patients, we launched the Watch, Wait, Worry campaign, to raise awareness of what Watch and Wait is. The campaign aims to: share stories of patients coming to terms with a CLL diagnosis and Watch and Wait; and call for improvements in both support and information provision.

- The campaign launched with a Facebook Live of our campaign clock, as the All Party Parliamentary Group on Blood Cancer discussed Watch and Wait in parliament.
- The Campaigns and Advocacy team exhibited the Watch, Wait, Worry campaign to haematology clinicians and nurses at the British Society of Haematology (BSH) conference.
- Top CLL clinicians, Prof. Chris Fegan and Niamh Appleby, shared their explanations of Watch and Wait and showed their support for the campaign in videos from the BSH conference.
- Four patients and Campaigns and Advocacy Officer, Beth, featured in local media to share their stories and promote the campaign, including written features in newspapers and a feature story on the BBC Three Counties radio health show.
- Four CLL patients (Marc, Wendy, Paul and Erica) shared their stories in our Watch, Wait, Worry videos.
- Three people won our campaign clocks in a competition on social media.
- Our new 'Living Well with Watch and Wait' guide for patients launched, helping signpost patients and their families to information and support that they may need during Watch and Wait.
- Your advice for living well on Watch and Wait was shared on social media.
- The key findings and recommendations of our new report were also highlighted on social media.
- A Watch, Wait, Worry package containing the report and guide was sent to every haematology department in the UK.

Copies of all our reports can be downloaded from our website www.leukaemiacare.org.uk

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Supporting individuals who are struggling to access treatment so they don't face unnecessary obstacles to treatment;

We produced 12 issues of our advocacy toolkit – factsheets explaining key issues that may affect patients accessing treatment. These were downloaded 518 times and the topics covered were

- “Right to treatment – England – NICE recommendation”
- “What is a biosimilar?”
- “What is immunotherapy?”
- “Clinical Trials”
- “Individual Funding Requests” (England, Scotland, Wales and Northern Ireland)
- “NHS England – Your Right to Choose”
- “CAR-T Therapy”
- “Carer's Rights”
- “Minimal Residual Disease”
- “Treatment Free Remission”
- “Using the internet safely to find information”
- “Power of Attorney”

Signposting to appropriate organisations so patients and carers receive the best support for them regardless of who provides it.

We continue to signpost patients and carers to the most appropriate support with most signposting conducted via our helpline, in our patient information booklets, our website and through our hospital support worker at Heartlands Hospital in Birmingham and Good Hope Hospital in Sutton Coldfield.

Communicating with patients, carers, healthcare professionals and fundraisers and the general public so they know about our services and become inspired to support the charity.

Our nationwide regional co-ordinators made 222 hospital visits raising awareness of the services available to patients and healthcare professionals and identifying need for further support.

9,000 people liked our Facebook page - an increase of 5,838 since 2016/17. We ended the year with 5,592 twitter followers and 6,539 Instagram followers.

Using social media, we were able to reach 7,260,060 people.

575,713 people visited our website in 2017/2018 - an increase of 57% compared to 2016/17.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (<https://www.fundraisingregulator.org.uk/>) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2017/18, the charity received seven suppression requests through the Fundraising Preference Service and these were all actioned.

We work in partnership with East London Textiles Limited (ELTL) to raise funds from textile recycling. ELTL distribute charity bags on our behalf to households throughout the UK offering people the opportunity to donate their unwanted clothing and raise money on behalf of Leukaemia Care. The charity incurs no upfront costs and is guaranteed a set monthly payment over the next five years. We secured a Home Office Exemption Order which allows ELTL (the commercial participator) to collect on our behalf without seeking a licence to do so from each individual council which has secured an uplift in the monthly payment awarded to Leukaemia Care.

We work closely with ELTL to ensure compliance with the agreed standards that come with the Home Officer Exemption Order including the resolution of any complaints or queries received.

In 2017/18, Leukaemia Care received 193 complaints relating to the charity bags; 123 related to bags that had not been picked up, 49 to unwanted bags and the remaining 22 to other issues.

Our complaints procedure can be found on our website <https://www.leukaemiacare.org.uk/about-us/>

Events

265 people raised £523,907 on our behalf from taking part in the London Marathon, UK challenges, overseas events, skydives, RideLondon and other running events.

Business and community

£237,549 was raised from community donations and events, static collection tins, Christmas cards, schools, businesses, payroll giving, in memory giving, regular giving, recycling and ebay.

Grants and trusts

We raised £11,635 from grants and trusts and are grateful to the following for their support: Joseph Strong Frazer Trust, Templeton Goodwill Trust, James Mackanass Family Trust, QBE Foundation, Lasletts Charitable Trust, One Stop Carriers for Causes, Foundation Scotland, The John Avins Trust, DC Leggats Trust, and Blackmore and Son.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Legacies

We wish to honour the following individuals for their generous gifts which enable us to continue supporting patients and carers through a blood cancer diagnosis and subsequent treatment.

Kathleen Robbins, Olive Cope, Jean Robinson, Maria Hussey, Frederick Boulton, Alice Martin, Raymond Wilson, Enid Cartwright, David Fergusson, Rose McMillan and Albert Perryman.

Pharmaceutical funding

We work with the pharmaceutical industry to ensure that they take the interests of patients into account when developing new drugs and treatments for blood cancer patients. Additionally, we also receive funding from a number of pharmaceutical companies.

Collaborative working and financial support from pharmaceutical companies is so important to allow us to continue our vital work. But we recognise the need for such partnerships to be transparent to ensure that we can withstand analysis of our decisions whilst also honouring our freedom to provide care and support to blood cancer patients and their families.

Any funds received from the pharmaceutical industry are received and dispersed strictly within the guidelines laid down by the 'ABPI Code of Practice, Clause 24 – Relationships with Patient Organisations' and Leukaemia CARE's Code of Practice. Our Code of Practice is intended to minimise the impact of any real, potential or perceived conflict of interest that may arise when patient organisations accept financial support from pharmaceutical companies.

For further information and to download a copy of our code of practice please visit our website <https://www.leukaemiacare.org.uk/working-with-the-pharmaceutical-industry>

In 2017/18, we received £155,731 from the pharmaceutical industry and would like to thank the following companies for their support:

Abbvie (£10,000), Abbvie Europe (£30,204), Amgen (£10,000), Bristol Myers Squibb (£22,000), Celgene (£15,000), Gilead (£5,350), Incyte (£15,000), Janssen (£10,000), Novartis (£18,317), Pfizer (£2,060) and Takeda (£17,800).

Volunteers

In 2017/18, volunteers contributed 7,282 hours against various tasks. Our volunteers fundraise, review patient literature, speak at conferences, provide one to one support, run support groups, provide emotional support on the help line, and share their stories among many other things.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Leukaemia Care medical advisory panel

We are grateful to our panel for their expertise and support. Their contributions are wide and varied; writing and reviewing content for our patient information, speaking at patient and carer conferences, providing information for patient submissions for drugs going through the NICE, SMC and AWMSG drug appraisal processes, reviewing projects and presenting at our nurse conferences.

Professor Andrew Pettitt MA, MB, BChir, PhD, MRCP, MRCPPath
Royal Liverpool University Hospital.

Professor Antonio Pagliuca MB, BS, MA, FRCP, FRPath
King's College Hospital.

Dr Panos Kottaridis, MSc, PhD, FRCP, MRCPPath
Royal Free Hospital Hampstead.

Dr John Donohue Clinical Psychologist in Haematology and Oncology
Russells Hall Hospital, Dudley

Dr Mark Crowther BSc (Med Sci), MB ChB, MSc, MRCP, FRCPPath
Worcestershire Royal Hospital

Dr Salim Shafeek MD, DipRCPath, FRCP, FRCP(ed), FRCPPath
Worcestershire Royal Hospital

Dr Fiona Clark MB ChB, FRCP (London), FRCPPath
Worcestershire Royal Hospital

Professor Claire Harrison DM FRCP FRCPPath
Guy's and St Thomas', London

Professor Peter Hillmen MB ChB PhD FRCP FRCPPath
St James's University Hospital, Leeds

Dr Emmanouil (Manos) Nikolousis MRCP, FRCPPath, PhD
Consultant Haematologist
Heart of England NHS Trust

Dr Juliet Mills BSc, MB BS, M.D., MRCP, FRCPPath
Consultant Haematologist
Worcestershire Royal Hospital

Simon Cheesman
Lead Pharmacist, Haematology
University College London Hospitals

Professor Christopher Fegan MB, MD, FRCP, FRCPPath
Professor of Haematology
University Hospital of Wales

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Financial review

The results for the year are set out in the financial statements commencing on page 22. The financial statements show incoming resources of £1,263,555 compared to incoming resources in 2017 of £1,108,665. Trustees would like to thank all staff and volunteers for the continuing hard work and commitment that have made this possible.

Total reserves now stand at 2,208,611 (2017: £2,217,371) of which £118,681 (2017: £150,887) are restricted in application and £977,277 (2017: £1,252,817) have been designated by the trustees to match the tangible fixed assets of the charity and fund certain projects identified as being required in the immediate future. With regards the latter the funds for projects of £111,065 are likely to be spent over the next three years, those connected to tangible fixed assets relate predominantly to the freehold property and are likely, given current market conditions, to remain whilst the charity continues to own title to the same. Funds remaining for general use are £1,112,653 (2017: £813,667).

The Trustees consider the results for the year and the financial position at the balance sheet date to be satisfactory.

The Trustees carry out an annual detailed review of the Charity's activities and produce a comprehensive strategic plan which sets out the major opportunities for the delivery of CARE and support. The Trustees monitor progress against the strategic objectives set out in the plan on a quarterly basis, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises, inter alia:

- a comprehensive annual review to identify, where possible, the risks which the Charity may face during the forthcoming year;
- the establishment, where possible, of contingency plans to meet likely/anticipated risk(s);
- the establishment of systems and procedures to mitigate such risks and the implementation of procedures to minimise any real or potential impact on the Charity should any such risk(s) materialise;
 - the prioritisation of the Charity's activities both actual and planned;
- the preparation and monitoring of meaningful and timely financial and management information.

The strategic plan referred to above focuses on the delivery of care and support to persons affected by blood and lymphatic cancers and various other matters associated therewith. Successful implementation of the plan is dependent upon the Charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

Reserves Policy

The Trustees have forecast the level of free reserves (those funds not tied up in tangible fixed assets or categorised as designated or restricted funds) that the Charity will require to sustain its operations over the period when it is anticipated that there may be some reduction in income. Such reduction may lead to the curtailment or cancellation (temporarily or otherwise, depending on the specific nature of the income reduction) of projects detailed in the strategic plan (whether in progress or not yet commenced). The overriding concern of the Trustees at such a time will be the maintenance of the Charity's essential core services.

Having regard to the foregoing, and with the assistance of professional advice and guidance, the Trustees consider that the most appropriate level of free reserves to be held by the Charity should be sufficient to cover between nine and twelve months of budgeted forecast expenditure.

Whilst the current level of income generated may prove sufficient to meet identified requirements, it is the Trustees' view that there should be sufficient free reserves available to provide financial flexibility, having regard to known and anticipated future expenditure and to provide contingency funding to meet any shortfall in income generation and/or any unplanned emergency expenditure which may be required.

The policy of the Trustees, therefore, is to closely monitor the financial and operational activities of the Charity and to continue to maintain free reserves within the parameters identified above.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually and recommendations made to Trustees. Day to day investment management is delegated to an authorised professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be available at short notice to support the on-going activities of the Leukaemia Care Society.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

Plans for the future

Leukaemia Care's 2018 strategic plan has been developed from measured outcomes over the past two years and evidenced proposals. The 2018 to 2021 strategy has also been aligned with working towards addressing 9 of the 10 recommendations made in the "Living with Leukaemia" report published in September 2017 by Leukaemia Care.

Initiatives for 2018 to 19 include:

Launch nine new patient information booklets covering chronic lymphocytic leukaemia, chronic myeloid leukaemia and acute lymphocytic leukaemia.

Translate more of our publications into the top six languages spoken in the UK: Welsh, Gujarati, Punjabi, Polish, Urdu and Bengali.

Produce patient friendly summaries on video of the latest advances presented at international haematology conferences.

Provide hospital support workers at three more hospital sites – a source of information, advice and emotional support for patients at haematology clinics.

Launch 13 new support groups across the UK.

Publish four issues of Leukaemia Matters – one to be online only.

Run a 12-month pilot for patients with chronic lymphocytic leukaemia – providing people with buddies who support them by email and phone. This is in partnership with the Chronic Lymphocytic Leukaemia Support Association and health professionals at Leicester and Nottingham Hospitals.

Hold four patient information days focused purely on managing fatigue in Oxford, Sheffield, Cardiff and Edinburgh.

Hold two nurse masterclasses in Birmingham and London focussing on chronic and acute leukaemias.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

Award £20,000 in bursaries to support nurses in their delivery of patient care.

Launch our e-learning academy for haematology nurses working with leukaemia patients accredited by the Royal College of Nursing – free to access by nurses.

Publish four issues of Nursing Matters with two online only issues.

Run two GP events in partnership with regional RCGP faculties aimed at raising awareness of the signs and symptoms of leukaemias to improve early diagnosis.

Investigate early diagnosis initiatives for pharmacists, dentists and nurse practitioners.

Continue to raise awareness of the signs and symptoms of leukaemia with the general public through our annual “Spot Leukaemia” campaign during Blood Cancer Awareness Month.

Appoint an Advocacy Caseworker to assist patients and their families struggling to access services.

Develop medical and patient advisory panels to inform the development of our services to patients, their families and healthcare professionals.

Publish the results of our 2017 survey of 2,884 leukaemia patients during Blood Cancer Awareness Month in September with key recommendations.

We will invite patients, carers and health professionals to take part in our most ambitious leukaemia survey to date.

Continuing from our # WatchWaitWorry campaign, we are going to work towards clinician’s adopting guidelines on managing blood cancer patients on watch and wait.

We will begin to hold awareness days, giving people the chance to learn about the work we are doing to help people live better lives with blood cancer.

We are going to strengthen our commitment to good governance by recruiting more Trustees with key skills in primary care, nursing, business and law.

Structure, governance and management

The Leukaemia Care Society trading as Leukaemia Care was founded in 1967 and was registered in September 1969 with the Charity Commission under charity number 259483; and with the Office of the Scottish Charity Regulator (OSCR) on 25 January 2008 under the charity number SC039207.

The charity is an unincorporated association and is governed by the Constitution revised on 20 September 2008.

The trustees, principal addresses and professional advisors of the charity are listed on the Reference and Administrative Information page.

The Trustees who served during the year and up to the date of signature of the financial statements were:

C. Matthews Maxwell (Chair)

A. Podesta (Vice-chair)

W Davies (Treasurer)

D Moseley

Mr K Griffin

Dr M Nikolousis

D Moseley resigned at the meeting held on the date of approval to the accounts, 25 July 2018.

THE LEUKAEMIA CARE SOCIETY

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

The Charity is controlled by a Trustee Board which has the powers to conduct all affairs of the Charity (subject to some limitations) and which comprises a Chairman, Vice Chairman, Treasurer and such others that the Charity may appoint from time to time. All Trustees are members of the Trustee Board.

The Trustees have overall responsibility for the strategy and operation of the charity, setting budgets (including remuneration policies) and controlling all major decisions. The Trustee Board meets at least 3 times a year.

The CEO and Deputy CEO with the support of staff are responsible for executing the strategy and managing the organisation's activities.

New Trustees are often already aware of the work of the Charity as a result of their own experiences. They are invited to visit headquarters meeting with the staff to gain an understanding of the day to day activities. They are also invited to attend both patient and fundraising events throughout the year to see the charity in action.

Alongside they receive copies of relevant publications from the Charity Commission and the Office of the Scottish Charity Regulator (OSCR) to assist them in their duties.

The Trustees have examined the major strategic, business and operational risks which the charity faces and confirm that systems have been established to enable regular reports to be produced so that the necessary steps can be taken to lessen these risks. A risk register has been established and will be reviewed and updated annually.

There is no special relationship with any other charity, but there are occasions when we are asked to support a beneficiary of other charities. We have also assisted other charitable projects that are within the scope of our objects and may work in partnership with charities whose aims are related to our own.

The Trustees' report was approved by the Board of Trustees.



C. Matthews Maxwell (Chair)

Trustee

Dated: 25 July 2018

THE LEUKAEMIA CARE SOCIETY

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 MARCH 2018

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales and in Scotland requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources of the Charity for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the provisions of the trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of accounts may differ from legislation in other jurisdictions.

THE LEUKAEMIA CARE SOCIETY

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE LEUKAEMIA CARE SOCIETY

Opinion

We have audited the financial statements of The Leukaemia Care Society (the 'Charity') for the year ended 31 March 2018 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 March 2018 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the accounts section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the accounts in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the Trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The Trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE LEUKAEMIA CARE SOCIETY

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE LEUKAEMIA CARE SOCIETY

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <http://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Other matter


Your attention is drawn to the fact that the charity has prepared financial statements in accordance with "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

This has been done in order for the financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

THE LEUKAEMIA CARE SOCIETY

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF THE LEUKAEMIA CARE SOCIETY



**Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP**

25 July 2018

**Chartered Accountants
Statutory Auditor**

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the Charity by virtue of its eligibility for appointment as auditor of a company under of section 1212 of the Companies Act 2006

THE LEUKAEMIA CARE SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2018

	Notes	Unrestricted funds £	Restricted funds £	Total 2018 £	Total 2017 £
<u>Income and endowments from:</u>					
Donations and legacies	3	463,422	145,304	608,726	538,685
Fundraising income	4	625,336	-	625,336	552,528
Investments	5	29,231	-	29,231	16,503
Other income	6	262	-	262	949
Total income		1,118,251	145,304	1,263,555	1,108,665
<u>Expenditure on:</u>					
Raising funds	7	379,324	-	379,324	331,329
Charitable activities	8	726,871	177,510	904,381	643,382
Total resources expended		1,106,195	177,510	1,283,705	974,711
Net gains/(losses) on investments	14	(1,250)	-	(1,250)	8,787
Net incoming/(outgoing) resources		10,806	(32,206)	(21,400)	142,741
Other recognised gains and losses					
Revaluation of tangible fixed assets		12,640	-	12,640	12,640
Net movement in funds		23,446	(32,206)	(8,760)	155,381
Fund balances at 1 April 2017		2,066,484	150,887	2,217,371	2,061,990
Fund balances at 31 March 2018		2,089,930	118,681	2,208,611	2,217,371

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.


THE LEUKAEMIA CARE SOCIETY


BALANCE SHEET

AS AT 31 MARCH 2018

	Notes	2018		2017	
		£	£	£	£
Fixed assets					
Tangible assets	16		866,212		864,652
Investments	17		209,282		110,290
			<u>1,075,494</u>		<u>974,942</u>
Current assets					
Debtors	19	74,317		53,337	
Investments	20	400,000		-	
Cash at bank and in hand		938,102		1,437,808	
			<u>1,412,419</u>	<u>1,491,145</u>	
Creditors: amounts falling due within one year	22	(111,129)		(66,314)	
Net current assets			<u>1,301,290</u>		<u>1,424,831</u>
Total assets less current liabilities			<u>2,376,784</u>		<u>2,399,773</u>
Creditors: amounts falling due after more than one year	23		(168,173)		(182,402)
Net assets			<u><u>2,208,611</u></u>		<u><u>2,217,371</u></u>
Income funds					
Restricted funds	25		118,681		150,887
<u>Unrestricted funds</u>					
Designated funds	26	977,277		1,252,818	
General unrestricted funds		1,112,653		813,666	
			<u>2,089,930</u>		<u>2,066,484</u>
			<u><u>2,208,611</u></u>		<u><u>2,217,371</u></u>

The financial statements were approved by the Trustees on 25 July 2018


C. Matthews Maxwell (Chair)
Trustee


W Davies (Treasurer)
Trustee

THE LEUKAEMIA CARE SOCIETY

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2018

	Notes	2018 £	£	2017 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	29		(2,646)		111,581
Investing activities					
Purchase of tangible fixed assets		(12,729)		(6,011)	
Proceeds on disposal of tangible fixed assets		262		949	
Purchase of investments		(128,107)		(53,675)	
Proceeds on disposal of investments		27,865		52,495	
Interest received		29,231		16,503	
Net cash (used in)/generated from investing activities			(83,478)		10,261
Financing activities					
Repayment of bank loans		(13,582)		(13,406)	
Net cash used in financing activities			(13,582)		(13,406)
Net (decrease)/increase in cash and cash equivalents			(99,706)		108,436
Cash and cash equivalents at beginning of year			1,437,808		1,329,372
Cash and cash equivalents at end of year			1,338,102		1,437,808
Relating to:					
Cash at bank and in hand			938,102		1,437,808
Short term deposits included in current asset investments			400,000		-
Bank overdrafts included in creditors payable within one year			-		-

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2018

1 Accounting policies

Charity information

The Leukaemia Care Society is an unincorporated charity which was formed in 1967 and is governed by its Constitution which was revised on 20 September 2008. It is a registered charity in both England and Wales and in Scotland. Its charity number in England and Wales is 259483 and in Scotland it is SC039207.

1.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The Charity is a Public Benefit Entity as defined by FRS 102.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Incoming resources

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

1 Accounting policies

(Continued)

Event income is recognised as an incoming resource on receipt, as this is when it becomes measurable.

Investment income is included in the SOFA in the year in which it is receivable.

Voluntary income is recognised as an incoming resource when receivable, except insofar as when it is incapable of financial measurement.

Time spent by volunteers is recorded and valued as income at an hourly rate payable in the market place for the services provided. An equivalent amount is included as expenditure.

1.5 Resources expended

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	over 50 years
Computers and other equipment	over 3 or 4 years
Fixture and fittings	over 10 years
Motor vehicles	over 5 years

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually, and whenever there is an indication that the asset may be impaired.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

1 Accounting policies

(Continued)

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

The Charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

2 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by that review process.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total 2018	Total 2017
	£	£	£	£
Donations and gifts	139,440	7,500	146,940	170,279
Legacies receivable	235,244	-	235,244	161,316
Corporate grants and donations	25,714	137,804	163,518	138,326
Donated goods and services	63,024	-	63,024	68,764
	<u>463,422</u>	<u>145,304</u>	<u>608,726</u>	<u>538,685</u>
For the year ended 31 March 2017	<u>379,544</u>	<u>159,141</u>		<u>538,685</u>

4 Fundraising income

	2018	2017
	£	£
Fundraising events - all unrestricted	<u>625,336</u>	<u>552,528</u>

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

5 Investments

	2018	2017
	£	£
Rental income	22,500	11,346
Investment income	1,680	2,253
Interest receivable	5,051	2,904
	<u>29,231</u>	<u>16,503</u>

All income relates to unrestricted funds.

6 Other income

	2018	2017
	£	£
Net gain on disposal of tangible fixed assets	<u>262</u>	<u>949</u>

7 Raising funds

	2018	2017
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	120,769	108,370
Advertising	18,734	7,144
Database	4,595	10,970
Other fundraising costs	35,936	34,152
Staff costs	150,451	126,378
Depreciation and impairment	3,040	2,749
Investment management fees	1,438	1,073
Support costs (see note 10)	40,432	35,687
Governance costs (see note 10)	3,929	4,806
	<u>379,324</u>	<u>331,329</u>

The above expenditure relates to unrestricted fundraising.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

8 Charitable activities

	2018	2017
	£	£
Staff costs	381,170	281,924
Depreciation and impairment	20,769	18,771
Care Awareness costs	78,949	34,375
Conferences	29,077	32,337
Care Line costs	25,103	9,903
Journey costs	37,346	29,359
Campaign costs	63,687	28,995
Other charitable activities	31,544	21,303
Nurse e-learning tool	27,000	-
Donated Care Line services	63,024	64,194
GP's e-learning tool	19,009	7,654
Training	-	1,661
Database costs	4,595	10,970
	<u>781,273</u>	<u>541,446</u>
Grant funding of activities (see note 9)	19,596	11,250
Share of support costs (see note 10)	94,343	79,966
Share of governance costs (see note 10)	9,169	10,720
	<u>904,381</u>	<u>643,382</u>
Analysis by fund		
Unrestricted funds	726,871	
Restricted funds	177,510	
	<u>904,381</u>	
For the year ended 31 March 2017		
Unrestricted funds		549,710
Restricted funds		93,672
		<u>643,382</u>

9 Grants payable

Grants of £19,596 were paid to individuals, being bursaries to nurses as provided for in designated funds.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

10 Support costs

	Support costs £	Governance costs £	2018 £	2017 £	Basis of allocation
Other staff costs	2,636	-	2,636	1,721	Staff time
Rent, rates and insurance	7,457	-	7,457	9,455	Staff time
Heat and light	6,620	-	6,620	4,753	Staff time
Repairs and renewals	8,298	-	8,298	10,177	Staff time
Printing, postage and stationery	13,026	-	13,026	13,616	Staff time
Telephone	10,548	-	10,548	11,516	Staff time
Motor and other travel	9,529	-	9,529	4,813	Staff time
Subscriptions	1,258	-	1,258	1,633	Staff time
Consultancy	15,562	-	15,562	33,846	Staff time
Other office costs	9,415	-	9,415	8,721	Staff time
Website costs	38,843	-	38,843	5,089	Staff time
Bank charges	50	-	50	-	Staff time
Sundry expenses	8,103	-	8,103	6,786	Staff time
Bank loan and other bank interest	3,430	-	3,430	3,527	Staff time
Audit fees	-	4,000	4,000	3,343	Staff time
Legal and professional	-	3,813	3,813	4,943	Staff time
Trustee and meeting expenses	-	3,556	3,556	3,479	Staff time
Consultancy	-	1,729	1,729	3,761	Staff time
	<u>134,775</u>	<u>13,098</u>	<u>147,873</u>	<u>131,179</u>	
Analysed between					
Fundraising	40,432	3,929	44,361	40,493	
Charitable activities	94,343	9,169	103,512	90,686	
	<u>134,775</u>	<u>13,098</u>	<u>147,873</u>	<u>131,179</u>	

11 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

Fees payable	2018 £	2017 £
Audit of the annual accounts	4,000	3,343
	<u>4,000</u>	<u>3,343</u>

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

12 Trustees

The Charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 trustees for the current year (2017: 2) were £3,454 (2017: £3,479).

None of the Trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CK Chartered Accountants to prepare the payroll, W Davies, trustee, is a partner in this firm. The services are provided on an arms length basis and the amount paid during the year amounted to £1,296 (2017: £1,337).

All trustees are covered by an indemnity insurance policy costing £750 (2017: £750)

13 Employees

Number of employees

The average monthly number employees during the year was:

	2018 Number	2017 Number
Training and provision of care	12	10
Fundraising and publicity	10	4
Accounts and administration	3	3
	<u>25</u>	<u>17</u>

Employment costs

	2018 £	2017 £
Wages and salaries	482,745	328,831
Social security costs	40,707	66,151
Other pension costs	8,169	13,320
	<u>531,621</u>	<u>408,302</u>

The remuneration of key management personnel through payroll and other fees is £103,451 (2017: £129,962).

There were no employees whose annual remuneration was £60,000 or more.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

14 Net gains/(losses) on investments

	2018	2017
	£	£
Revaluation of investments	(1,492)	3,857
Gain/(loss) on sale of investments	242	4,930
	<u>(1,250)</u>	<u>8,787</u>

15 Taxation

There is no taxation payable during the year as the activities undertaken by Leukaemia Care fall within the charitable objectives of the charity.

16 Tangible fixed assets

	Freehold buildings	Computers and other equipment	Fixture and fittings	Motor vehicles	Total
	£	£	£	£	£
Cost					
At 1 April 2017	842,598	177,266	14,656	17,199	1,051,719
Additions	-	12,729	-	-	12,729
Disposals	-	-	-	(17,199)	(17,199)
At 31 March 2018	<u>842,598</u>	<u>189,995</u>	<u>14,656</u>	<u>-</u>	<u>1,047,249</u>
Depreciation and impairment					
At 1 April 2017	-	165,911	3,957	17,199	187,067
Depreciation charged in the year	12,640	9,703	1,466	-	23,809
Eliminated in respect of disposals	-	-	-	(17,199)	(17,199)
Revaluation	(12,640)	-	-	-	(12,640)
At 31 March 2018	<u>-</u>	<u>175,614</u>	<u>5,423</u>	<u>-</u>	<u>181,037</u>
Carrying amount					
At 31 March 2018	<u>842,598</u>	<u>14,381</u>	<u>9,233</u>	<u>-</u>	<u>866,212</u>
At 31 March 2017	<u>842,598</u>	<u>11,355</u>	<u>10,699</u>	<u>-</u>	<u>864,652</u>

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

17 Fixed asset investments

	Listed investments £	Cash in portfolio	Total £
Cost or valuation			
At 1 April 2017	100,113	10,177	110,290
Additions	128,107	(28,107)	100,000
Valuation changes	(1,492)	-	(1,492)
Other cash movements	222	21	243
Profit on disposal	242	-	242
Disposals	(28,099)	28,099	-
	<u>199,093</u>	<u>10,190</u>	<u>209,283</u>
Carrying amount			
At 31 March 2018	<u>199,093</u>	<u>10,190</u>	<u>209,283</u>
At 31 March 2017	<u>100,113</u>	<u>10,177</u>	<u>110,290</u>
		2018	2017
		£	£
Investments at fair value comprise:			
Managed investment portfolio		<u>199,093</u>	<u>100,113</u>

Fixed asset investments revalued

Investments are included at market value based on mid-market prices at the the accounting reference date. On an historical cost basis the value of investments would be £196,473 (2017: £96,001).

18 Financial instruments	2018 £	2017 £
Carrying amount of financial assets		
Debt instruments measured at amortised cost	57,259	40,815
Equity instruments measured at cost less impairment	199,093	100,113
	<u> </u>	<u> </u>
Carrying amount of financial liabilities		
Measured at amortised cost	(232,457)	(206,215)
	<u> </u>	<u> </u>

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

19 Debtors	2018	2017
Amounts falling due within one year:	£	£
Trade debtors	10,273	11,496
Prepayments and accrued income	64,044	41,841
	<u>74,317</u>	<u>53,337</u>
	<u><u>74,317</u></u>	<u><u>53,337</u></u>
20 Current asset investments	2018	2017
	£	£
Unlisted investments	400,000	-
	<u>400,000</u>	<u>-</u>
	<u><u>400,000</u></u>	<u><u>-</u></u>
21 Loans and overdrafts	2018	2017
	£	£
Bank loans	182,173	195,755
	<u>182,173</u>	<u>195,755</u>
	<u><u>182,173</u></u>	<u><u>195,755</u></u>
Payable within one year	14,000	13,353
Payable after one year	168,173	182,402
	<u>182,173</u>	<u>195,755</u>
	<u><u>182,173</u></u>	<u><u>195,755</u></u>
Amounts included above which fall due after five years:		
Payable by instalments	(111,459)	(126,710)
	<u>(111,459)</u>	<u>(126,710)</u>
	<u><u>(111,459)</u></u>	<u><u>(126,710)</u></u>

The long-term loan is secured via a first legal mortgage over freehold property at 1 Birch Court, Blackpole East, Worcester, WR3 8SG.

The loan carries interest at 1.4% above the Barclays Bank plc base rate, at the year end the effective rate charged was 1.9%.

22 Creditors: amounts falling due within one year	Notes	2018	2017
		£	£
Bank loans	21	14,000	13,353
Other taxation and social security		13,140	9,844
Trade creditors		55,055	14,835
Accruals and deferred income		28,934	28,282
		<u>111,129</u>	<u>66,314</u>
		<u><u>111,129</u></u>	<u><u>66,314</u></u>

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

23 Creditors: amounts falling due after more than one year

	Notes	2018 £	2017 £
Bank loans	21	168,173	182,402

24 Retirement benefit schemes

Defined contribution schemes

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £8,169 (2017 - £13,320).

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

25 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Balance at 31 March 2018 £
	Balance at 1 April 2017 £	Incoming resources £	Resources expended £	
The Grant Generation Fund	47	-	(47)	-
The Lily Blaen Hope Fund	54,437	-	(10,068)	44,369
Information Booklets	7,270	35,000	(42,270)	-
Nurse Conferences	-	3,333	(2,277)	1,056
Conferences	2,131	3,000	(5,131)	-
Care Helpline Costs	13,446	1,000	(14,431)	15
GP e-learning tool	21,168	17,600	(38,768)	-
Support Groups	-	3,000	(1,952)	1,048
Nurse Advisor	47,388	3,500	(26,570)	24,318
Student/Education	5,000	-	-	5,000
Worcester Support Group	-	2,000	(720)	1,280
Nursing Matters	-	8,334	(7,455)	879
Ward Support Heartlands	-	500	(500)	-
Ward Support Goodhope	-	2,000	(1,680)	320
Nurse e-learning	-	33,333	(20,971)	12,362
Glasgow Area	-	2,500	-	2,500
Buddy Scheme	-	30,204	(4,670)	25,534
	150,887	145,304	(177,510)	118,681
	150,887	145,304	(177,510)	118,681

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

25 Restricted funds

(Continued)

The Grant Generation Fund: this represents donations made specifically to be expended on grants to assist both adults and children.

The Lily Blaen Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

Conferences: grants in support of conferences held in the year.

Care Helpline costs: this represents income received specifically to meet the costs of the Care line.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Support groups: this represents income specifically to meet the costs of support groups sponsored by Leukaemia Care.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Educational - to raise awareness.

Nursing matters and nurse e-learning - funds to support the advancement of knowledge in the nursing profession.

Glasgow Area - funds to support services in the Glasgow area.

Buddy Scheme - one to one support for patients with chronic lymphocytic leukaemia.

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

26 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 April 2017 £	Movement in funds			Balance at 31 March 2018 £
		Incoming resources £	Resources expended £	Transfers £	
Fixed asset fund	864,651	-	-	1,561	866,212
Strategic implementation fund	358,166	-	(277,101)	-	81,065
Nurses' bursaries fund	30,000	-	(22,500)	22,500	30,000
	<u>1,252,817</u>	<u>-</u>	<u>(299,601)</u>	<u>24,061</u>	<u>977,277</u>

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the three year strategy adopted by the Trustees on 4 April 2016.

Nurses' Bursaries: This fund is designated for the grant of bursaries to nurses to fund courses as part of their continuing professional development.

27 Analysis of net assets between funds

	Unrestricted funds £	Designated funds £	Restricted funds £	Total £
Fund balances at 31 March 2018 are represented by:				
Tangible assets	-	866,212	-	866,212
Investments	209,282	-	-	209,282
Current assets/(liabilities)	794,443	388,166	118,681	1,301,290
Long term liabilities	(168,173)	-	-	(168,173)
	<u>835,552</u>	<u>1,254,378</u>	<u>118,681</u>	<u>2,208,611</u>

THE LEUKAEMIA CARE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2018

28 Operating lease commitments

At the reporting end date the Charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2018 £	2017 £
Within one year	5,402	354
Between two and five years	6,493	-
	<u>11,895</u>	<u>354</u>

Lessor

At the reporting end date the Charity had contracted with tenants for the following minimum lease payments:

	2018 £	2017 £
Between two and five years	<u>33,750</u>	<u>56,250</u>

29 Cash generated from operations

	2018 £	2017 £
(Deficit)/surplus for the year	(21,400)	142,741
Adjustments for:		
Investment income recognised in statement of financial activities	(29,231)	(16,503)
Gain on disposal of tangible fixed assets	(262)	(949)
Gain on disposal of investments	(242)	(4,930)
Fair value gains and losses on investments	1,492	(3,857)
Depreciation and impairment of tangible fixed assets	23,809	21,520
Movements in working capital:		
(Increase) in debtors	(20,980)	(26,306)
Increase/(decrease) in creditors	44,168	(135)
Cash (absorbed by)/generated from operations	<u>(2,646)</u>	<u>111,581</u>

